For COVID-19 Treatment FDA approves Remdesivir

COVID-19 treatment with remdesivir

COVID-19 hospitalization and deaths are on the rise across the globe. Furthermore, doctors have serious concerns regarding the spread of the virus during winter. More than 1124 coronavirus patients’ deaths occurred in America on Wednesday. The Covid-19 is coming back with its second wave. Furthermore, the arrival of winter together with a coronavirus rise can result in devastating outcomes. However, the FDA, after extensive tests approves Remdesivir for the treatment of COVID-19.

In-Depth Study of New Anti-Viral Drug for Treating COVID-19

Remdesivir is an antiviral drug. Furthermore, it targets a range of viruses. The development of the drug occurred a decade ago. Furthermore, it affects the viruses responsible for respiratory syncytial virus and hepatitis C. The use against respiratory diseases made it a great option for COVID-19 treatment. Researchers also investigated the effect of remdesivir on the Ebola virus. 

Furthermore, studies in cells and animals show that remdesivir affects viruses of the coronavirus family, such as Middle East Respiratory Syndrome (MERS). Moreover, the studies suggest a reasonable effect of the drug on severe acute respiratory syndrome (SARS). 

ALSO READ: COVID-19 Vaccine Volunteer Dies After Volunteering for Oxford And AstraZeneca’s Vaccine

Remdisivir disrupts the production cycle of the virus. The drug interferes with the key enzyme of the coronavirus. Moreover, this key enzyme is essential for the replication of the RNA of coronavirus. Thus, researchers are working on remdesivir to find the possibility of it being able to treat SARS-COV-2. Furthermore, to determine the effect of remdesivir on COVID-19

FDA Approval For Remdesivir 

The US Food and Drug Administration is responsible for approving any new drug. Furthermore, the FDA analyzes all drug-related issues. After analyzing all the information, investigation-results, and performance of the drug in clinical trials FDA approves a drug for the market. 

Gilead Sciences is a drug-maker. He reported Thursday that the FDA has approved remdesivir for the treatment of coronavirus infection. Furthermore, the drug is on the market with the brand name Veklury. The remdesivir has also been used under emergency use authorization since May. 

Gilead Sciences submitted a study published in the New England Journal of Medicine to the FDA. The data shows that remdesivir shortens the course of COVID-19 infection in hospitalized patients. Furthermore, hospitalization reduces from an average of 15 days to about 11 days. 

However, the WHO sponsored a study that suggests that remdesivir does not help patients in recovery or survival. The FDA, however, after considering data submitted by the drug-maker, approved its use as it shortens hospitalization.

Opinion On Remdesivir Approval For COVID-19 Treatment

Rick Bright is the former director of the Biomedical Advanced Research and Development Authority (BARDA). He said he was not impressed by remdesivir. Furthermore, this anti-viral drug was not able to lower the mortality rate. According to him, remdesivir shows no impact on shortening or lengthening the hospital stay. However, the drug does show marginal benefits.

ALSO READ: New CDC Guidance – Close Contact With COVID-19

According to FDA Commissioner Dr. Stephen Hahn, FDA approves remdesivir for treating COVID-19 after carefully analyzing the data. Furthermore, the drug will be an important scientific milestone in the COVID-19 pandemics. Moreover, a combination of remdesivir with antibacterial-drugs can help to formulate new medicine. Furthermore, the combined drugs can be more effective against COVID-19.

The Food and Drug Administration will continue its Coronavirus Treatment Acceleration Program. Furthermore, the organization will continue to make new medical products accessible to patients. In addition, the FDA will support other new inventive-drugs. Moreover, the FDA will continue to determine the effectiveness of innovative-drugs. The FDA will also monitor their safety profiles and determine whether the benefits of the new-drug outweigh their risks.

About the author


Adeena Tariq Lari

The author is a graduate of dental surgery from the Dow University Health Sciences, Karachi. She has an academic background in content writing as well as English literature, giving her an edge in the field. Adeena is always curious about physical and mental health. She is always passionate about research and delivering high-quality reliable content to users.

Add Comment

Click here to post a comment